Urethral and prostatic α1-adrenoreceptors are thought to mediate the dynamic component of benign prostatic obstruction. Pharmacologic antagonists of these receptors can notably improve symptoms, even in patients who have undergone prostatectomy. This Review provides an update on the distribution of α1-adrenoreceptors in relevant urinary tract structures and how this might affect therapy with antagonists.
- Karl-Erik Andersson
- Christian Gratzke